ARRIVENT BIOPHARMA, INC. Number of Reportable Segments
ARRIVENT BIOPHARMA, INC. (AVBP) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ARRIVENT BIOPHARMA, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- ARRIVENT BIOPHARMA, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |